Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | IL31RA |
Clinical data | |
Other names | CIM-331 |
Routes of administration | Subcutaneous injection |
ATC code | |
Pharmacokinetic data | |
Metabolism | Proteolytic enzymes |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]